{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:43:58Z","timestamp":1769759038074,"version":"3.49.0"},"reference-count":37,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Introduction. The Italian Committee for Tailored BIOlogic Therapy (ITABIO), in a first report, has reviewed the literature to identify the best strategy for the choice of second-line biologic therapy in patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA). To verify the application of ITABIO recommendations in real life and how the recommendations perform in maintaining the health status of patients affected by inflammatory arthritis (RA, SpA, PsA), a database has been developed by Pharmaceutical Governance to evaluate the appropriateness of prescriptions. Methods. We have analyzed retrospectively 616 patients, 288 (46.7%) affected by RA, 117 (19%) affected by SpA, and 211 (34.3%) affected by PsA. Age, sex, diagnosis, current treatment, previous treatments with csDMARDs, b-DMARDs, ts-DMARDs, presence of risk factors for cardiovascular (CV) events, liver disease, infections, extra-articular manifestations such as interstitial lung disease (ILD) for RA, enthesitis, dactylitis, uveitis, inflammatory bowel disease for SpA and PsA, neoplasms, diabetes, presence or absence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) for RA were evaluated. Results. The percentage of treatments with anti-TNF biosimilars was 65.1, 52.4, and 24.3% in SpA (76 patients(pt)), PsA (110 pt), and RA (69 pt), respectively. The percentage of monotherapy was 68% (418 pt) in the three diseases. For RA, 34.2% of patients were difficult to treat (D2T) (98 pt), 54.8% (157 pt) were in monotherapy (tocilizumab-sarilumab-upadacitinib-filgotinib). Abatacept was the most prescribed treatment in RF and ACPA-positive patients and in those with ILD. The anti-IL-17A secukinumab was prescribed in 12% of SpA, of which 71% had enthesitis and dactylitis (14 pt). Ixekizumab was prescribed in 10.4% of PsA patients over 65 years with previous CV events, enthesitis, and dactylitis (21 pt). Apremilast was present in 71% of PsA with previous cancer. Conclusions. The cross-sectional analysis of prescriptions in patients with RA, SpA, and PsA demonstrates how the ITABIO recommendations can guide towards the correct appropriateness of prescription. RA and especially D2T-RA remains the disease with the greatest therapeutic failures, with the highest percentage of monotherapy (anti-IL-6 and Jak-i) and of discontinuation of MTX.<\/jats:p>","DOI":"10.3390\/jpm15080366","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T09:59:13Z","timestamp":1754906353000},"page":"366","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Single-Center Cross-Sectional Analysis of Patients with RA, SpA, and PsA: Data from the Prescription Database"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8180-6660","authenticated-orcid":false,"given":"Maurizio","family":"Benucci","sequence":"first","affiliation":[{"name":"Rheumatology Unit, S. Giovanni di Dio Hospital, USL-Toscana-Centro, 50143 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca Li","family":"Gobbi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, S. Giovanni di Dio Hospital, USL-Toscana-Centro, 50143 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5009-1161","authenticated-orcid":false,"given":"Emanuele Antonio Maria","family":"Cassar\u00e0","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, S. Giovanni di Dio Hospital, USL-Toscana-Centro, 50143 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4748-8954","authenticated-orcid":false,"given":"Anna Lucia","family":"Marigliano","sequence":"additional","affiliation":[{"name":"Pharmaceutical Governance and Appropriateness of Prescription Unit, Hospital S. Stefano, USL-Toscana-Centro, 59100 Prato, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Mannoni","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, P. Palagi Hospital, USL-Toscana-Centro, 50122 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Benvenuti","sequence":"additional","affiliation":[{"name":"Multidimensional Medicine Department, USL-Toscana Centro, 50143 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.semarthrit.2017.03.008","article-title":"Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"47","author":"Cantini","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/14740338.2022.2020247","article-title":"Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements","volume":"21","author":"Cantini","year":"2022","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Manfredi, A., Fornaro, M., Bazzani, C., Perniola, S., Cauli, A., Rai, A., Favalli, E.G., Rossini, M., Foti, R., and Conti, F. (2024). Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: Data from GISEA registry. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1349533"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"152313","DOI":"10.1016\/j.semarthrit.2023.152313","article-title":"Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study","volume":"64","author":"Simon","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.42730","article-title":"Methotrexate Safety and Efficacy in Combination Therapies in Patients with Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial","volume":"76","author":"Lend","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ard-2024-226024","article-title":"Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: Data from a randomised controlled trial","volume":"83","author":"Lend","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13075-024-03323-8","article-title":"Long-term effects of abatacept on atherosclerosis and arthritis in older vs. younger patients with rheumatoid arthritis: 3-year results of a prospective, multicenter, observational study","volume":"26","author":"Yamada","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"ref_11","first-page":"855","article-title":"Effect of abatacept versus conventional synthetic disease modifying anti-rheumatic drugs on rheumatoid arthritis-associated interstitial lung disease Korean","volume":"39","author":"Lee","year":"2024","journal-title":"J. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Parisi, S., Ditto, M.C., Ghellere, F., Panaro, S., Piccione, F., Borrelli, R., and Fusaro, E. (2025). Update on tocilizumab in rheumatoid arthritis: A narrative review. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1470488"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","first-page":"1043","article-title":"Effectiveness and safety of filgotinib in rheumatoid arthritis patients: Data from the GISEA registry","volume":"42","author":"Fornaro","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40262-024-01370-7","article-title":"Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review","volume":"63","author":"Emaus","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/rheumatology\/keaf035","article-title":"Rheumatoid factors revisited in the age of biologic therapy","volume":"64","author":"Avci","year":"2025","journal-title":"Rheumatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Adorni, M.P., Papotti, B., Borghi, M.O., Raschi, E., Zimetti, F., Bernini, F., Meroni, P.L., and Ronda, N. (2023). Effect of the JAK\/STAT Inhibitor Tofacitinib on Macrophage Cholesterol Metabolism. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612571"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10067-021-06003-z","article-title":"Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: A systematic review and network meta-analysis","volume":"41","author":"Li","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Benucci, M., Li Gobbi, F., Damiani, A., Russo, E., Guiducci, S., Manfredi, M., Lari, B., Grossi, V., and Infantino, M. (2024). Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA-i Study). J. Clin. Med., 13.","DOI":"10.3390\/jcm13061821"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/rheumatology\/keac563","article-title":"Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: A multicentre cohort study","volume":"62","author":"Giollo","year":"2023","journal-title":"Rheumatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/keae318","article-title":"Prevalence and characteristics of adults with difficult-to-treat rheumatoid arthritis in a large patient registry","volume":"64","author":"Paudel","year":"2025","journal-title":"Rheumatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40744-025-00747-9","article-title":"Effective Second-Line b\/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b\/tsDMARDs from the FIRST Registry","volume":"12","author":"Kanda","year":"2025","journal-title":"Rheumatol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/00002512-200724030-00005","article-title":"Risk: Benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis","volume":"24","author":"Fleischmann","year":"2007","journal-title":"Drugs Aging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jbspin.2015.07.004","article-title":"Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients","volume":"83","author":"Zbinden","year":"2016","journal-title":"Jt. Bone Spine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103530","DOI":"10.1016\/j.autrev.2024.103530","article-title":"Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence","volume":"23","author":"Sun","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/BOR.0000000000000999","article-title":"Cardiovascular disease in spondyloarthritis: A narrative review of risk factors and the effect of treatments","volume":"36","author":"Sen","year":"2024","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Picchianti-Diamanti, A., Aiello, A., De Lorenzo, C., Migliori, G.B., and Goletti, D. (2025). Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1494283"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/rheumatology\/keab784","article-title":"Chilles study group. Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: Results from a phase 3b trial","volume":"61","author":"Behrens","year":"2022","journal-title":"Rheumatology"},{"key":"ref_30","first-page":"e60980","article-title":"The Impact of Interleukin-17 Inhibitors on Major Adverse Cardiovascular Events in Psoriasis or Psoriatic Arthritis Patients Naive to Biologic Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"16","author":"Ni","year":"2024","journal-title":"Cureus"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/acr.23738","article-title":"Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical Trials","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Care Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13075-019-1831-0","article-title":"Ixekizumab and complete resolution of enthesitis and dactylitis: Integrated analysis of two phase 3 randomized trials in psoriatic arthritis","volume":"21","author":"Gladman","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e15306","DOI":"10.1111\/dth.15306","article-title":"Psoriatic, patients with a history of cancer: A real-life experience with Apremilast treatment for 104 weeks","volume":"35","author":"Bernardini","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40257-023-00783-7","article-title":"Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behcet\u2019s Syndrome","volume":"24","author":"Mease","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_35","first-page":"947","article-title":"Novel insights into the management of rheumatoid arthritis: One year in review 2024","volume":"42","author":"Molteni","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4081\/reumatismo.2021.1367","article-title":"The Italian Society for Rheumatology recommendations for the management of axial spondyloarthritis","volume":"73","author":"Manara","year":"2021","journal-title":"Reumatismo"},{"key":"ref_37","first-page":"991","article-title":"Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology","volume":"35","author":"Marchesoni","year":"2017","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/8\/366\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:24:29Z","timestamp":1760034269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/8\/366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jpm15080366"],"URL":"https:\/\/doi.org\/10.3390\/jpm15080366","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]}}}